Clinical Trial Update: A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intravitreal JNJ-81201887 (AAVCAGsCD59) versus sham for geographic atrophy due to age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• JNJ-81201887 (AAVCAGsCD59) (AAVCAGsCD59)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED